{"name":"Lidds AB","slug":"lidds-ab","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"2-Hydroxyflutamide","genericName":"2-Hydroxyflutamide","slug":"2-hydroxyflutamide","indication":"Prostate cancer","status":"phase_1"}]}],"pipeline":[{"name":"2-Hydroxyflutamide","genericName":"2-Hydroxyflutamide","slug":"2-hydroxyflutamide","phase":"phase_1","mechanism":"Anti-androgen receptor antagonist","indications":["Prostate cancer"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiZEFVX3lxTE1CZWRVSnBSbnFpUUo0U2xLZEwtbzc0NHZ6aXNuaHdDdExycExjZEJnckxjdmlrWURYcHg1TGJZVi1zX0pJdmhWd25LYkNrM2FjamZNQi1qMzdLVHV0SldjRGFrOU4?oc=5","date":"2026-04-01","type":"pipeline","source":"GuruFocus","summary":"OSTO Stocks: Research Stocks from OSTO - GuruFocus","headline":"OSTO Stocks: Research Stocks from OSTO","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAJBVV95cUxNLVRiQjM3WTYyeFNCblg0R3VxT01Hek9tS0V0cDZ3aGFYb0VLMG5TQmFqaFo5MVdtYU9ETm1USlpyODR6aU9zX3lyT0l2ME9qYUx2QmxnSGRpaVdtcUFoRzgwMEMtTzZ2c0M5NWVFVzd5VTZNVnhSUWpCRFRkUWRwMFN6OUcxWThfMEVlWlFwRDVnT2l4dEZlMVpJZDBEUWQ4Ym44SHdzV25fM01KTWR2cC04ZE52YlNlQzJwTHdEOFdTamQxbFQ0WjBWVEhtTkRwbmt0b0NDX0w0VDJyaHNreTBybmhLZldIZWhJWVJab0o4UjB1a2ZzQnEtcUdsQXExOV82UnMtblkybUNNM1UwWFV2b2Q?oc=5","date":"2026-02-09","type":"pipeline","source":"TradingView","summary":"LIDDS AB (publ): The liquidator intends to file for bankruptcy as the conditions for completing the liquidation are lacking - TradingView","headline":"LIDDS AB (publ): The liquidator intends to file for bankruptcy as the conditions for completing the liquidation are lack","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_1":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}